Step 1 topics → Biochemistry → Organelle Functions

Organelle Functions

USMLE Step 1 trap: Confuses free ribosome vs RER destinations for newly synthesized proteins. Cytosolic, nuclear, peroxisomal, and mitochondrial proteins are made on free ribosomes; only secreted, membrane, and lysosomal proteins are made on the RER.

Organelle functions are tested on USMLE Step 1 not as a laundry list of facts, but as a network of trafficking decisions and degradation pathways. The exam wants you to predict where a protein ends up, why it ends up there, and what breaks when that system fails. The four highest-yield angles are: which ribosomes make which proteins, how the Golgi tags lysosomal enzymes, what peroxisomes do that mitochondria cannot, and how ubiquitin-proteasome degradation differs from lysosomal degradation. Get these four right and you've covered the bulk of what appears on this topic.

The tricky part is that these concepts look simple in isolation but get scrambled when presented in a clinical vignette. A question might describe a child with accumulating very long chain fatty acids and ask you to identify the organelle — that's a peroxisome question dressed up as a metabolism question. Another might give you I-cell disease and ask why lysosomal enzymes are found in the blood instead of lysosomes — that's a Golgi tagging question. USMLE Step 1 loves this disguise: a clinical presentation that forces you to reason backward to the broken mechanism.

The four misconceptions in this topic all share the same root error: students mentally flatten the cell into a two-compartment system (ER vs. cytoplasm) and miss the specificity of each organelle's role. You need a more granular map — which ribosome, which tag, which organelle, which degradation pathway — and you need to know the disease that results when each step fails.

From real student decks
92%have cards covering this topic
70%have mature cards

Common misconceptions

Common mistake
Wrong: All proteins are synthesized on the rough ER.
Right: Cytosolic, nuclear, peroxisomal, and mitochondrial proteins are made on free ribosomes; only secreted, membrane, and lysosomal proteins are made on the RER.
The rough ER only handles proteins destined to leave the cell or be embedded in membranes — secreted proteins, membrane proteins, and lysosomal enzymes. Everything that stays inside the cytoplasm (enzymes, cytoskeletal proteins), goes to the nucleus, gets imported into mitochondria, or is targeted to peroxisomes is made on free ribosomes. The signal sequence on the growing polypeptide is what recruits the ribosome to the ER membrane — no signal sequence, no RER involvement.
Common mistake
Wrong: Lysosomal enzymes are sent directly from the RER to lysosomes.
Right: Lysosomal enzymes are tagged with mannose-6-phosphate in the Golgi, which directs them to lysosomes via clathrin-coated vesicles.
Lysosomal enzymes don't go straight from the RER to lysosomes — they make a required stop in the Golgi, where N-acetylglucosamine-1-phosphotransferase adds mannose-6-phosphate residues to their oligosaccharide chains. That tag is recognized by M6P receptors on vesicle membranes, directing the enzymes into clathrin-coated vesicles that fuse with late endosomes and eventually lysosomes. In I-cell disease, the phosphotransferase is defective, so enzymes never get tagged and are secreted extracellularly instead — this is the exact mechanism the exam tests.
Common mistake
Wrong: Very long chain fatty acid (VLCFA) beta-oxidation occurs in mitochondria.
Right: VLCFAs are oxidized exclusively in peroxisomes; mitochondria handle short, medium, and long chain fatty acids.
Mitochondria perform beta-oxidation on short, medium, and long chain fatty acids (up to about 20 carbons), but they physically cannot import VLCFAs (22+ carbons). Peroxisomes handle that initial shortening — they chew VLCFAs down to medium-chain fatty acids that can then enter mitochondria. When peroxisomes are absent or dysfunctional (Zellweger syndrome) or a specific VLCFA transporter is missing (adrenoleukodystrophy), VLCFAs accumulate in plasma and tissues, especially myelin — which explains the neurological presentations.
Common mistake
Wrong: Ubiquitin tags proteins for lysosomal degradation.
Right: Ubiquitin tags cytosolic proteins for degradation by the 26S proteasome, not the lysosome; lysosomes degrade extracellular and membrane proteins via endocytosis.
Ubiquitin is a cytosolic protein that tags other cytosolic proteins — it physically cannot reach the interior of lysosomes, and lysosomes don't have the proteasome machinery anyway. The ubiquitin-proteasome system degrades intracellular proteins (misfolded, damaged, or regulated for turnover), while lysosomes handle extracellular material brought in by endocytosis and membrane proteins internalized by autophagy or receptor-mediated endocytosis. Confusing these two pathways leads to wrong answers on questions about protein quality control and neurodegenerative disease mechanisms.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know which proteins are synthesized on free ribosomes versus the rough ER — the exam will give you a protein type (cytosolic enzyme, secreted hormone, lysosomal enzyme) and expect you to identify the correct ribosome location and trafficking route.
  2. Know the Golgi's role in lysosomal targeting — specifically that mannose-6-phosphate is added in the Golgi and acts as the zip code directing enzymes to lysosomes via clathrin-coated vesicles; I-cell disease is the classic test case for when this step fails.
  3. Know what peroxisomes do that mitochondria cannot — very long chain fatty acid (VLCFA) beta-oxidation is exclusively peroxisomal; the exam tests this through disorders like adrenoleukodystrophy and Zellweger syndrome, which present with VLCFA accumulation.
  4. Know the ubiquitin-proteasome pathway and how it differs from lysosomal degradation — ubiquitin tags cytosolic proteins for the 26S proteasome, not the lysosome; the exam may connect this to diseases like Parkinson's (Lewy bodies from failed proteasomal clearance) or ask you to distinguish the two degradation routes.

Can you avoid these mistakes?

A cell is synthesizing a cytosolic enzyme involved in glycolysis. Is this protein made on free ribosomes or the rough ER? What feature of the protein determines this, and how would your answer change if the protein were instead a lysosomal hydrolase?
A 1-year-old presents with coarse facial features, corneal clouding, and elevated lysosomal enzymes in the plasma. Intracellular enzyme levels in fibroblasts are low. What step in normal lysosomal targeting is defective, which organelle is responsible for that step, and what is the diagnosis?
A teenage boy develops progressive neurological deterioration and adrenal insufficiency. His plasma shows elevated very long chain fatty acids. Explain why these fatty acids accumulate — specifically, which organelle is dysfunctional and why mitochondria cannot compensate.
A researcher treats cells with a proteasome inhibitor and finds that misfolded cytosolic proteins accumulate. Would you expect lysosomal function to be affected? Why or why not — and what disease is associated with failed proteasomal clearance of alpha-synuclein?

Related topics

Nucleotide and Nucleic Acid Structure DNA Replication DNA Repair Pathways Mutations and Their Consequences

See how your Anki deck covers this topic.

Upload your deck for a free audit →